登录 | 注册    关注公众号  
微信公众号
搜索
 >  Protein>Her2 >HE2-H82E2

Biotinylated Human Her2 / ErbB2 Protein, His,Avitag™, premium grade

分子别名(Synonym)

ERBB2,CD340,HER-2,neu,HER2,MLN19,NEU,NGL,TKR1

表达区间及表达系统(Source)

Biotinylated Human Her2, His,Avitag, premium grade (HE2-H82E2) is expressed from human 293 cells (HEK293). It contains AA Thr 23 - Thr 652 (Accession # P04626-1).

Predicted N-terminus: Thr 23

It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

Request for sequence

蛋白结构(Molecular Characterization)

Her2 Structure

This protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

The protein has a calculated MW of 72.9 kDa. The protein migrates as 101 kDa±3 kDa under reducing (R) condition, and 94 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

标记(Labeling)

Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

蛋白标记度(Biotinylation)

As determined by Quantitative ELISA binding assay against streptavidin.

内毒素(Endotoxin)

Less than 0.01 EU per μg by the LAL method.

宿主蛋白残留(Host Cell Protein)

<0.5 ng/µg of protein tested by ELISA.

宿主核酸残留(Host Cell DNA)

<0.02 ng/μg of protein tested by qPCR.

无菌(Sterility)

Negative

支原体(Mycoplasma)

Negative.

纯度(Purity)

>95% as determined by SDS-PAGE.

>90% as determined by SEC-MALS.

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 24 months in lyophilized state;
  2. -70°C for 12 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

Her2 SDS-PAGE

Biotinylated Human Her2, His,Avitag, premium grade on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

SEC-MALS

Her2 SEC-MALS

The purity of Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) is more than 90% and the molecular weight of this protein is around 75-110 kDa verified by SEC-MALS.

Report

 

活性(Bioactivity)-FACS

Her2 FACS

2e5 of anti-Her2 CAR-293 cells were stained with 100 μL of 1 μg/mL of Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

Protocol

 

活性(Bioactivity)-ELISA

Her2 ELISA

Immobilized Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Pertuzumab Biosimilar with a linear range of 0.2-8 ng/mL (QC tested).

Protocol

Her2 ELISA

Immobilized Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Trastuzumab Biosimilar with a linear range of 0.2-2 ng/mL (Routinely tested).

Protocol

 

活性(Bioactivity)-SPR

Her2 SPR

Trastuzumab Biosimilar captured on Protein A Chip can bind Biotinylated Human Her2, His,Avitag, premium grade (Cat. No. HE2-H82E2) with an affinity constant of 7.49 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Protocol

 
评论(10)
  1. 177XXXXXXX7
  2. 3人赞
  3. 本次购买蛋白为bio-human-her2,his标签,用于BLI实验,检测抗体亲和力。从结果上来看属于慢结合慢解离。
  4. >
  5. 2021-11-25
  1. 339XXXXXXX
  2. 1人赞
  3. We use both the biotinylated and PE labeled version of this ERBB2 protein to detect our HER2-CAR in NK cells by flow cytometry. The biotinylated version works consistently well at a 1/200 dilution, and you can see a nice saturation curve if you titrate it. I do recommend making single use aliquots. The PE labeled also works well but you need to use a lot more of it.
  4. 2022-7-24
  1. 159XXXXXXX5
  2. 1人赞
  3. HER2是一种细胞膜表面结合受体酪氨酸激酶,通常参与导致细胞生长和分化的信号转导途径。购买此蛋白主要用于进行表征实验,实验结果符合预期。
  4. 2024-5-13
 
ACRO质量管理体系
 
 

背景(Background)

Human Epidermal growth factor Receptor 2 (HER2) is also called ERBB2, HER-2,HER-2 /neu, NEU, NGL,TKR1 and c-erb B2,and is a protein giving higher aggressiveness in breast cancers. It is a member of the ErbB protein family, more commonly known as the epidermal growth factor receptor family. HER2 is a cell membrane surface-bound receptor tyrosine kinase and is normally involved in the signal transduction pathways leading to cell growth and differentiation. HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to activate it. Approximately 30% of breast cancers have an amplification of the HER2 gene or overexpression of its protein product. Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. HER2 appears to play roles in development, cancer, communication at the neuromuscular junction and regulation of cell growth and differentiation .

文献引用(Citations)

 

前沿进展

Molecular Docking and Pharmacological In Silico Evaluation of Camptothecin and Related Ligands as Promising HER2-Targeted Therapies for Breast Cancer
Millan-Casarrubias, García-Tejeda, González-De la Rosa et al
Curr Issues Mol Biol (2025) 47 (3)
Abstract: Breast cancer is one of the leading causes of cancer-related mortality in women worldwide, highlighting the importance of effective therapies. This study evaluates the interaction between camptothecin, a potent anticancer agent, and two key receptors implicated in breast cancer progression: HER2 (human epidermal growth factor receptor 2) and EGFR (epidermal growth factor receptor), using molecular docking. The results reveal a stronger binding affinity between camptothecin and HER2 than EGFR, in contrast to neratinib, which demonstrated affinity exclusively for HER2. Camptothecin exhibits significant hydrophobic and pi-alkyl interactions with HER2, whereas its interactions with EGFR are primarily mediated by hydrogen bonds. Molecular dynamics (MD) simulations of the camptothecin-HER2 complex indicate stable binding, with minimal fluctuations observed over 100 nanoseconds, confirming the stability of the ligand-receptor interaction. Pharmacokinetic evaluations, based on Lipinski's rule of five, demonstrate that camptothecin adheres to essential drug-likeness parameters, suggesting favorable bioavailability. Furthermore, the analysis comparing the pharmacological properties of camptothecin with other well-known anticancer compounds, such as neratinib, shows that camptothecin exhibited superior compliance with drug-likeness rules. Despite its low solubility, the binding stability and pharmacokinetic profile suggest its potential as an effective therapeutic agent for breast cancer, particularly when combined with drug delivery systems that enhance solubility. This work underscores the importance of receptor-specific ligand interactions in drug design and highlights the need for further studies into camptothecin's clinical applications, especially in HER2-positive breast cancer treatment.
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024
Leigh, Ahmed, Aubin et al
Curr Oncol (2025) 32 (3)
Abstract: The Eastern Canadian Gastrointestinal Cancer Consensus Conference was an annual meeting that was held in St. John's, Newfoundland and Labrador, from 26 to 28 September 2024. This included experts in medical oncology, radiation oncology, surgical oncology, nuclear medicine, and general practitioners in oncology (GPO) from across the eastern Canadian provinces who are involved in the management of patients with gastrointestinal malignancies. This consensus statement generated by the conference addresses multiple topics, including the management of localized rectal cancer, liver-limited colorectal cancer, systemic therapy for advanced biliary tract cancers, radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs), systemic therapy for pancreatic and midgut well-differentiated NETs, and systemic therapy for HER2-positive gastroesophageal cancers.
Q-TWiST Analysis of Sacituzumab Govitecan vs. Chemotherapy in Previously Treated Patients with HR+/HER2- Metastatic Breast Cancer
Rugo, Bardia, Schmid et al
Curr Oncol (2025) 32 (3)
Abstract: In TROPiCS-02, sacituzumab govitecan (SG) demonstrated significantly longer overall survival and progression-free survival with improved quality of life vs. chemotherapy treatment of physician's choice (TPC) in patients with HR+/HER2- metastatic breast cancer (mBC). The safety profile was consistent with previous studies of SG. We assessed the benefit--risk profile of SG vs. TPC by integrating patient preferences with clinical benefits using Quality-adjusted Time Without Symptoms of disease progression or Toxicity of treatment (Q-TWiST) analysis in this study population. Survival time was partitioned into three health states: TOX (grade ≥3 treatment-emergent adverse events [TEAEs] after randomization/before disease progression), REL (disease progression until death or end of follow-up), and TWiST (time without progression or grade ≥3 TEAEs). Health state utility weights were obtained from the published literature. The established threshold for clinically important Q-TWiST gain is 10%. SG demonstrated significantly improved Q-TWiST vs. TPC (mean 9.7 vs. 8.1 months; difference 1.6 months; 95% CI, 0.5-2.7; p = 0.0067), which increased with longer follow-up. Relative Q-TWiST improvement met the threshold for clinical importance at 10.8%. Time in TOX was numerically higher with SG than TPC, and the difference stabilized over time. Q-TWiST supports a positive benefit-risk profile for SG over TPC in patients with pretreated HR+/HER2- mBC.
Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
Avci, Sahbazlar, Ekinci et al
Curr Oncol (2025) 32 (3)
Abstract: Background: Clinical trials in metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor-2 (HER2)-negative patients have shown that cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors both increase response rates and provide survival benefits. The efficacy of these therapies needs to be supported by real-life data. In this study, we aimed to evaluate treatment response, survival and affecting factors in patients with HR+/HER2- metastatic breast cancer (MBC) who were followed up with CDK 4/6 inhibitors in our center. Materials and methods: A retrospective analysis of 120 patients with HR+/HER2- MBC treated with ribociclib or palbociclib in combination with letrozole or fulvestrant was performed. Results: Median progression-free survival (mPFS) was 24 months in the general population, 27 months in the ribociclib arm and 20 months in the palbociclib arm, with no significant difference in progression-free survival (PFS) in both arms (p = 0.25). The mPFS was longer in the ribociclib + letrozole arm compared to palbociclib + letrozole (27 vs. 20 months, respectively). PFS was also longer in patients receiving ribociclib + fulvestrant compared to palbociclib + fulvestrant but not statistically significant (33 vs. 21 months, respectively). Median overall survival (mOS) was not reached, but 3-year overall survival (OS) was statistically significantly longer in the ribociclib arm (87% vs. 55.5%, respectively, p = 0.03). Conclusion: Palbociclib and ribociclib are first-line treatment options for metastatic HR+/HER2- disease and have similar efficacy. In our study, while the mPFS was not statistically significant in both arms, the 3-year OS rate was higher in the ribociclib arm and statistically significant. Our findings were confirmed in randomized studies comparing both agents head-to-head.
Showing 1-4 of 46217 papers.
Powered by BizGenius
 
 
货号/价格
产品推荐
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
Her2靶点信息
英文全称:Receptor protein-tyrosine kinase erbB-2
中文全称:受体蛋白酪氨酸激酶 erbB-2
种类:Homo sapiens
上市药物数量:39详情
临床药物数量:201详情
最高研发阶段:批准上市
查看更多信息
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定